Moleculin Biotech
$0.6089876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$0.608
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.0095 (+1.53%) Today
-$0.0215 (-3.42%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell MBRX and other stocks, options, ETFs, and crypto commission-free!
About MBRX
Moleculin Biotech, Inc. Common Stock, also called Moleculin Biotech, is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Read More Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
Employees
16
Headquarters
Houston, Texas
Founded
2015
Market Cap
37.26M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
4.82M
High Today
$0.6399
Low Today
$0.59
Open Price
$0.63
Volume
794.33K
52 Week High
$3.15
52 Week Low
$0.323
Collections
MBRX News
MBRX Earnings
-$0.20
-$0.13
-$0.07
$0.00
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
-$0.10 per share
Actual
Available Mar 19, After Hours